[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@BioSignal Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1990225480168169472.png) @BioSignal BioSignal

BioSignal posts on X about $legn, china, $bgne, $azn the most. They currently have XX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::1990225480168169472/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1990225480168169472/c:line/m:interactions.svg)

- X Week XX -XX%

### Mentions: XX [#](/creator/twitter::1990225480168169472/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1990225480168169472/c:line/m:posts_active.svg)


### Followers: XX [#](/creator/twitter::1990225480168169472/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1990225480168169472/c:line/m:followers.svg)

- X Week XX +26%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1990225480168169472/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1990225480168169472/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  XXXXX% [countries](/list/countries)  XXXXX% [technology brands](/list/technology-brands)  XXXXX% [finance](/list/finance)  XXXXX% [currencies](/list/currencies)  XXXXX% [cryptocurrencies](/list/cryptocurrencies)  XXXX%

**Social topic influence**
[$legn](/topic/$legn) 17.65%, [china](/topic/china) 17.65%, [$bgne](/topic/$bgne) 11.76%, [$azn](/topic/$azn) 11.76%, [vivo](/topic/vivo) 11.76%, [regeneron](/topic/regeneron) 11.76%, [$regn](/topic/$regn) 11.76%, [$275m](/topic/$275m) 11.76%, [$150m](/topic/$150m) 11.76%, [$gsk](/topic/$gsk) #5

**Top assets mentioned**
[AstraZeneca PLC (AZN)](/topic/$azn) [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) [GSK plc (GSK)](/topic/$gsk) [Eli Lilly and Company (LLY)](/topic/eli-lilly) [CG Oncology, Inc. Common stock (CGON)](/topic/$cgon) [Johnson & Johnson (JNJ)](/topic/$jnj) [Intellia Therapeutics, Inc (NTLA)](/topic/$ntla) [AbbVie Inc (ABBV)](/topic/$abbv) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Gilead Sciences, Inc. (GILD)](/topic/$gild) [BEAM (BEAM)](/topic/$beam) [Novartis AG (NVS)](/topic/novartis) [NVIDIA Corp. (NVDA)](/topic/$nvda) [IDEAYA Biosciences, Inc. Common Stock (IDYA)](/topic/$idya)
### Top Social Posts
Top posts by engagements in the last XX hours

"Data Drop: China Biotech is bringing the heat to ASH 2025. Three major clinical updates just hit the wire. Here is the breakdown of the Alpha: X. The Heavyweight: Legend Biotech ($LEGN) Asset: Lucar-G39D (Allogeneic CD19xCD20 CAR-T). The Data: XX% ORR XX% CR in LBCL. The Edge: This is "Off-the-shelf" (Gamma Delta T-cells). While CR is lower than Autologous the 6-month PFS of XX% suggests durability without the manufacturing wait time. X. The Myeloma Contender: 3SBio ($1530.HK) Asset: CS1 x BCMA Dual-Target CAR-T. The Data: IIT results show XXX% Overall Response in bone marrow (13 pts) with"  
[X Link](https://x.com/BioSignal/status/1996044986069254256)  2025-12-03T02:33Z XX followers, XX engagements


"The "King of BTK" throne is under siege. For years BeiGene ($BGNE) has dominated with Zanubrutinib. But at ASH 2025 Eli Lilly ($LLY) is bringing the heat with Pirtobrutinib. The Battle of the Blood Cancers: The Challenger: Lilly's Pirtobrutinib (Non-covalent BTK). New Data: Head-to-head vs Ibrutinib shows XX% ORR vs 78%. The Kill Shot: In chemo-naive patients Pirtobrutinib crushed standard chemo (HR 0.199). Implication: Lilly wants to move from "Last Line" rescue to "First Line" standard of care. The Defense: BeiGene isn't sitting still. The Wall: Sonrotoclax (BCL-2) + Zanubrutinib combo"  
[X Link](https://x.com/BioSignal/status/1996950956723085737)  2025-12-05T14:33Z XX followers, XX engagements


"BREAKING: China just fixed the biggest liability for its biotech sectorThe "Pricing Trap." The National Healthcare Security Administration (NHSA) just launched the China Drug Price Registration System. The Alpha: Until today if a Chinese biotech ($BGNE $LEGN) lowered prices to get into China's insurance (NRDL) US/EU payers would use that low price as leverage to crush their global margins ("International Reference Pricing"). The Fix: This new system creates a Dual-Track Pricing Model: Reimbursement Price: The discounted price paid by China (Hidden/Internal). Registered Market Price: The"  
[X Link](https://x.com/BioSignal/status/1996119724628070406)  2025-12-03T07:30Z XX followers, XX engagements


"CG Oncology ($CGON) has been the main trade for Bladder Cancer (NMIBC). But a new challenger just posted perfect data at SUO 2025. The New Data (High Dose Cohort): XXX% Complete Response in Carcinoma In Situ (CIS). XXX% Recurrence-Free Survival in Papilloma. Safety: Clean. No Dose-Limiting Toxicities. With the global BCG shortage the race for the NMIBC crown is wide open. ImmVira is already running a US Phase X. This is the asset that could disrupt the $CGON thesis. $CGON $MRK $JNJ $XBI $IBB"  
[X Link](https://x.com/BioSignal/status/1997570276880736542)  2025-12-07T07:34Z XX followers, XX engagements


"Why did AstraZeneca pay $1.2B for a Chinese CAR-T player (Gracell) when the market was already crowded The answer was just revealed at #ASH25: The "FasTCAR" Advantage. Most CAR-T therapies take weeks to manufacture. The cells get "exhausted" before they even reach the patient. AZD0120 (formerly GC012F) flips the script: X. The Speed (FasTCAR) Next-Day Manufacturing: AZN can produce these cells in XX hours. T-Cell Fitness: Because the process is so fast the T-cells remain "Young" (Naive/Central Memory phenotype). They are more aggressive and persist longer in the body. X. The Target"  
[X Link](https://x.com/BioSignal/status/1998470711393005663)  2025-12-09T19:12Z XX followers, XX engagements


"The "Holy Grail" of Cell Therapy just posted human proof-of-concept data. Most investors focus on Legend Biotech ($LEGN) or J&J ($JNJ). But a quiet revolution called "In Vivo CAR-T" just effectively rendered their supply chains obsolete. The News: Data from China just revealed results for ESO-T01 an In Vivo BCMA CAR-T. X Patients (Relapsed/Refractory Myeloma) XXX% Response Rate (4/4) XX% Strict Complete Remission (2/4) The Paradigm Shift: Current CAR-T ($LEGN) requires harvesting blood shipping it to a lab engineering it for X weeks and shipping it back. Cost: $500k. ESO-T01 is just an"  
[X Link](https://x.com/BioSignal/status/1996296886567985514)  2025-12-03T19:14Z XX followers, XX engagements


"Is CRISPR hitting a safety ceiling Regeneron ($REGN) just placed a $275M bet that says "Yes." The Context: Last month Regeneron and Intellia ($NTLA) had to pause their gene editing trial (NEX-z) due to severe liver toxicity. The suspected culprit The "Double Strand Breaks" (cutting DNA) required by traditional Cas-9. The Pivot: Regeneron just signed a massive deal ($150M upfront) with Tessera Therapeutics for a new asset in Alpha-1 (AATD). Tessera does not use CRISPR. They use "Gene Writing" (Mobile Genetic Elements). The Science Edge: CRISPR: Cuts the DNA helix - Triggers repair - Edits."  
[X Link](https://x.com/BioSignal/status/1996407111757316279)  2025-12-04T02:32Z XX followers, XX engagements


"The "Holy Grail" of oncology isn't a new target. It's deleting the factory. In 2025 alone Big Pharma ($AZN $ABBV $GILD $BMY) dropped $5B acquiring "In Vivo" CAR-T platforms. The goal: Turn a $500k personalized procedure into a single $50k injection. But there is a "Widowmaker" problem: Safety. When you manufacture cells inside the body you cannot "wash" them before infusion. If a Cytokine Storm (CRS) starts you can't stop the dosing. Its already in the patient. Enter the Chinese innovator: Unicar-Therapy (). While Western pharmas are focused on delivery (getting the gene to the T-cell) Unicar"  
[X Link](https://x.com/BioSignal/status/1997985520534933808)  2025-12-08T11:04Z XX followers, XX engagements


"The "One Mutation One Drug" economic model of Gene Editing is broken. It's too expensive for rare diseases. But David Liu (founder of $PRME and $BEAM) just published a solution in Nature that could fix XX% of all genetic diseases with a single approach. The Problem: "Nonsense Mutations" In roughly XX% of genetic diseases (like Tay-Sachs or Batten disease) the DNA has a typo that creates a "Stop Sign" too early. The cell stops building the protein halfway through rendering it useless. The Solution: PERT (Prime Editor-mediated Readthrough) Instead of fixing the typo letter-by-letter for every"  
[X Link](https://x.com/BioSignal/status/1995862272087130579)  2025-12-02T14:27Z XX followers, 1217 engagements


"Regeneron ($REGN) just validated the "Gene Writing" thesis with a massive high-conviction bet. They are deploying $275M ($150M upfront) to partner with Tessera Therapeutics on TSRA-196 for Alpha-1 Antitrypsin Deficiency (AATD). The Alpha: The deal structure is a 50:50 profit split. Regeneron is notoriously conservative. For them to offer equal terms on a preclinical asset the primate data (showing high liver specificity and no off-target edits) must be spectacular. The Landscape: This is a direct shot at the AATD heavyweights. $NTLA (CRISPR/Cas9) $ARWR (RNAi - chronic treatment) $BEAM (Base"  
[X Link](https://x.com/BioSignal/status/1997494779169718322)  2025-12-07T02:34Z XX followers, XX engagements


"BREAKING: Novartis ($NVS) just signed a massive $1.75B deal with Relation Therapeutics to hunt for new dermatology targets. The "Alpha" isn't just the dollar figureit's the technology. Relation uses a "Lab-in-the-Loop" AI platform and is backed by Nvidia ($NVDA) and $GSK. Big Pharma is officially paying a premium to outsource discovery to the AI-native biotechs. Deal terms: $55M Upfront / $1.7B Milestones. $NVS $NVDA $GSK $XBI $IBB"  
[X Link](https://x.com/BioSignal/status/1998581189754630327)  2025-12-10T02:31Z XX followers, XX engagements


"BREAKING: GSK ($GSK) has officially terminated its collaboration with IDEAYA Biosciences ($IDYA) returning full global rights to two clinical-stage assets. The returned programs: IDE275 (Werner Helicase) IDE705 (Pol Theta) This marks the final dissolution of their $3.1B partnership from 2020 (MAT2A was returned previously). GSK is effectively exiting early-stage synthetic lethality. The Investment View: The market typically sells on "Pharma Exits" assuming the data is bad. However IDEAYA's primary value driver is Darovasertib (Uveal Melanoma) not these assets. With major Phase 2/3 data for"  
[X Link](https://x.com/BioSignal/status/1998708527033102641)  2025-12-10T10:57Z XX followers, XX engagements